Free Newsletter
Icahn officially puts Biogen under siege
Is Biogen Idec ready for the Icahn onslaught? Activist shareholder and infamous thorn in management's side Carl Icahn made his proxy-fight threats official Friday with a Securities and Exchange Commission filing. Icahn outlined his pitch to take over four board seats, plus fix the size of the board at 13 and move Biogen's state of incorporation to shareholder-friendly state North Dakota.
Icahn has been goosing Biogen management for some 18 months now, ever since he strong-armed the company into putting itself up for sale. Then, after Biogen failed to find a buyer, he mounted a proxy fight to put his own people in three board seats, saying that the company had deliberately sabotaged its own auction process. And now there's this year's model.
Meanwhile, Icahn is stirring up trouble at Amylin, trying to push his five nominees onto that company's board of directors. (Another minority investor is pressing for its own slate of five, too.) He's a busy, busy man.
- read the Wall Street Journal story
Related Articles:
Amid proxy fight, Biogen chief earns $11.3M
Icahn on the prowl for Biogen, too
Icahn makes play for Amylin control
Biogen works to stave off proxy fights
Comments
Please let me know if you need CRO support for cinical trial in India, USA, EU cotnries and Japan.
Please contact me. Regards.
Dr. Srivastava, 908-720-9315
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: